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Abstract: Background and Aims: Studies in South Asian population show that low maternal 
vitamin B12 associates with insulin resistance and small for gestational age in the offspring. 
Low vitamin B12 status is attributed to vegetarianism in these populations. It is not known 
whether low B12 status is associated with metabolic risk of the offspring in whites, where 
the childhood metabolic disorders are increasing rapidly. Here, we studied whether maternal 
B12 levels associate with metabolic risk of the offspring at birth. Methods: This is a  
cross-sectional study of 91 mother-infant pairs (n = 182), of white Caucasian origin living 
in the UK. Blood samples were collected from white pregnant women at delivery and their 
newborns (cord blood). Serum vitamin B12, folate, homocysteine as well as the relevant 
metabolic risk factors were measured. Results: The prevalence of low serum vitamin B12 
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(<191 ng/L) and folate (<4.6 μg/L) were 40% and 11%, respectively. Maternal B12 was 
inversely associated with offspring’s Homeostasis Model Assessment 2-Insulin Resistance 
(HOMA-IR), triglycerides, homocysteine and positively with HDL-cholesterol after 
adjusting for age and BMI. In regression analysis, after adjusting for likely confounders, 
maternal B12 is independently associated with neonatal HDL-cholesterol and homocysteine 
but not triglycerides or HOMA-IR. Conclusions: Our study shows that low B12 status  
is common in white women and is independently associated with adverse cord  
blood cholesterol. 
Keywords: vitamin B12; maternal; offspring; metabolic risk; lipids 
 
1. Introduction 
The prevalence of childhood obesity is increasing rapidly [1,2]. Recently, the Early Childhood 
Longitudinal Study demonstrated that 27.3% of children were either overweight or obese by the time 
they enter kindergarten in the United States [1]. Higher rate of childhood obesity is a likely contributor 
for the increasing incidence of type 2 diabetes (T2D) earlier in life as well as pre-gestational and 
gestational diabetes (GDM) in women [3]. It is known that childhood obesity independently predicts 
obesity and metabolic disorders in the adulthood [4]. Children born with lower HDL and higher 
triglyceride levels were small for gestational age (SGA) and had higher abdominal circumference [5]. It 
is known that both higher abdominal circumference and SGA are associated with future development of 
T2D and GDM [6,7] in many populations.  
Although current adverse lifestyle (nutrition and physical inactivity) contributes to obesity, a growing 
body of evidence links nutrient imbalance in early life to the development of metabolic disorders in 
childhood and in adults [8]. Many studies support this link including the Dutch-famine study. Individuals 
exposed to nutritional imbalance during pregnancy are likely to be obese, have early onset of coronary 
artery disease, T2D and worse cognitive performances as adults [9]. Emerging evidence from clinical 
studies show that key maternal micronutrients involved in the one-carbon metabolism (1-C) can cause 
adverse metabolic programming. Independent studies from South Asia have demonstrated that children 
born to mothers with low vitamin B12 [10,11] and higher folate [12] have greater insulin resistance. In 
addition, low maternal B12 levels independently contributed to the risk of small for gestational age 
(SGA), which has been shown to increase the metabolic risk of the offspring [13]. Vegetarianism is the 
likely cause of high prevalence of low B12 levels in these population [14]. In a Brazilian pregnancy 
cohort, low maternal B12 was associated with lower levels of the methyl donor (S-adenosyl 
methionine—SAM) in the cord blood [15]. A study in a Chinese population demonstrated that low 
maternal B12 is common during pregnancy and is associated with an altered methylation pattern of the 
insulin growth factor 2 (IGF2) promoter region in the cord blood [16], highlighting a potential role of 
B12 on fetal growth. Further, animal studies showed that maternal vitamin B12 deficiency resulted in 
higher adiposity, insulin resistance, blood pressure [17] and adverse lipid profile in the offspring [18,19]. 
These investigations provide evidence that low maternal B12 could be an independent determinant of 
adverse metabolic phenotypes in the offspring.  
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Recently, we demonstrated in Europeans and Indians with T2D that vitamin B12 deficiency is 
associated with adverse lipid profile [20]. Re-analysis of the UK National Diet and Nutrition Survey 
data showed that low vitamin B12 levels (<191 ng/L) is common in the adult population (10%) and in 
women of reproductive age (14%) [21]. Our preliminary study of white pregnant women showed that 
the rate of low B12 status was as high as 20% at 16–18 weeks of gestation [22].  
Despite the evidence that vitamin B12 deficiency is a potential contributor for adverse offspring 
metabolic phenotypes and the prevalence of low B12 status is increasing in White Caucasian population, 
the link between maternal B12 status and metabolic risk at birth is unexplored in the White Caucasian 
population. Therefore, the objective of our study was to investigate whether maternal B12 levels in white 
women independently associate with the metabolic risk at birth.  
2. Methods 
2.1. Study Population 
The study was conducted in University Hospital Coventry Warwickshire (UHCW), Coventry, UK. 
All study participants were pregnant women delivering at 39–40 weeks of gestation. The Coventry local 
research ethics committee approved the study, and all patients gave written informed consent (Research 
Ethics Committees 07/H1210/141). Women with known chronic diseases were excluded. Maternal data 
including parity, smoking, BMI and birth weight were collected from pregnancy records. Folic acid 
supplement use collected but detailed dietary history was not recorded. Maternal BMI measured 
routinely at the first pregnancy visit (before 10 weeks of gestation). We collected 182 maternal venous 
and cord blood samples (91 mother-newborn pairs) at the time of delivery. Extrapolating from our 
preliminary studies [21,22], we anticipated around 20%–25% of the mothers to have low levels of 
vitamin B12 (<191 ng/L). To detect a similar proportion of low B12 status a sample size of 100–120 
was required. The samples were collected in the fasting state, in tubes without anticoagulant and 
centrifuged at 2000 rpm/10 min. Serum was separated, aliquoted and stored at −80 °C until analysis. 
2.2. Analytical Determinations 
Serum glucose, cholesterol, triglycerides, HDL cholesterol were determined using an auto analyser 
Synchron CX7 (Beckman Coulter, Fullerton, CA, USA) based on enzymatic colorimetric assays. Insulin 
was measured using Invitrogen ELISA kit (Camarillo, CA, USA) according to manufacturer’s 
instructions. LDL cholesterol was calculated using Friedewald formula. Insulin resistance (HOMA-IR) 
was calculated by the Homeostasis Model Assessment 2 computer model (HOMA2) using fasting insulin 
and glucose levels [10]. Serum B12 and folate were determined by electrochemiluminescent 
immunoassay using a Roche Cobas immunoassay analyzer (Roche Diagnostics UK, Burgess Hill, UK). 
Similar to other studies [20,23,24], we have used 191–663 ng/L for serum Vitamin B12 and  
4.6–18.7 μg/L for serum folate as normal range, respectively. The inter-assay coefficient of variations 
for B12 and folate were 3.9% and 3.7%, respectively. To avoid potential bias, all the biochemical 
analyses were conducted in a single batch to minimise assay variation. All the laboratory personnel were 
blinded and did not have any access to the clinical data. Serum homocysteine was determined by stable 
isotopic dilution analysis liquid chromatography (LC-MS/MS) [25] using a Waters Equity UPLC system 
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(Waters, Milford, CT, USA) coupled to an API 4000 tandem mass spectrometer (Applied Biosystems, 
Warrington, UK). Due to the uncertainty of defining deficiencies of serum vitamin B12 and folate levels 
during pregnancy and cord blood, the terms “low B12 status” and “low folate status” were used 
throughout the manuscript if the levels were below 191 ng/L and 4.6 μg/L, respectively. 
2.3. Statistical Analysis 
Continuous data are reported either as mean ± standard deviation (SD) or geometric mean with 95% 
confidence intervals (CI). Categorical data are reported in numbers (percentages). The distributions of 
the maternal and neonatal parameters such as vitamin B12, folate, cholesterol, triglycerides, HDL, LDL, 
glucose, insulin, HOMA-IR and homocysteine concentrations were skewed; these data were  
log-transformed before analyses. Student’s t-test was used for comparison of groups. Bivariate 
correlations were done using Pearson test. Variables that showed significant associations with dependent 
variable (neonatal metabolic risk factors) were included as independent variables in the multiple linear 
regression analyses. To facilitate comparison, dependent and independent variables were converted into 
standard deviation scores (SDS). The data are presented as SD change in offspring outcome per SD 
change in maternal vitamin B12, folate and homocysteine. Associations between maternal vitamin B12, 
folate and homocysteine concentrations and offspring outcomes were examined in multivariate linear 
regression using 3 models. Model 1: unadjusted; Model 2: adjusted for maternal age, BMI, glucose, 
insulin, parity, folic acid supplement use, smoking, vitamin B12, folate and homocysteine; Model 3: 
Model 2 + respective maternal variable. All tests were two-sided, and p values of <0.05 were considered 
to be statistically significant. All analyses were performed using SPSS Statistics version 21 (IBM Corp, 
Armonk, NY, USA). 
3. Results 
3.1. B12, Folate and Homocysteine Status 
The clinical characteristics of mothers and neonates are shown in Table 1. The prevalence of serum 
low vitamin B12 and folate status in women during pregnancy were 40% and 11% in mothers and 29% 
and 0% in neonates, respectively (Table 1). In cord blood, all the biochemical parameters were 
significantly lower than in maternal serum, except for the B12 and folate levels (Table 1). Children born 
to mothers with low B12 status had significantly lower B12 levels compared to those born to mothers 
with normal levels (Table 2). Mothers with higher parity and smoking had lower B12 levels. Those with 
self-reported folic acid supplement use had higher B12 and lower homocysteine levels (Table 3). 
Maternal B12, folate and homocysteine showed strong positive correlation with the respective offspring 
indices (B12: r = 0.648, folate: r = 0.706, homocysteine: r = 0.756, all p < 0.0001) (Supplementary 
Figure S1a–c). Neonatal homocysteine showed negative correlation with maternal B12 and folate (B12:  
r = −0.409, p < 0.0001; folate: r = −0.346, p < 0.001; Supplementary Figure S2a,b). 
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Table 1. Clinical characteristics of mothers and neonate. 
 
Mother Neonate 
n = 91 n = 91 
Age (years) 32.7 ± 5.9 a - 
Weight (Kg) 77.7 ± 18.1 3.57 ± 0.26 
Height (m) 1.62 ± 0.09 - 
BMI (early pregnancy) (kg/m2) 29.4 ± 6.2 - 
Glucose (mmol/L) 4.37 ± 0.42 3.88 ± 0.52 
Insulin (mIU/L) 11.6 (12.9, 17.4) b 8.01 (8.62, 11.9) 
Triglycerides (mmol/L) 2.69 (2.62, 3.06) 0.23 (0.22, 0.26) 
Cholesterol (mmol/L) 6.48 (6.31, 6.89) 1.68 (1.63, 1.84) 
LDL cholesterol (mmol/L) 3.53 (3.46, 3.95) 0.82 (0.79, 0.95) 
HDL cholesterol (mmol/L) 1.56 (1.53, 1.72) 0.74 (0.72, 0.83) 
HOMA-IR 1.37 (1.55, 2.09) 0.99 (1.04, 1.41) 
Vitamin B12 (ng/L) 218 (213, 289) 290 (292, 418) 
Low B12 status (%)  36 (40) c 26 (29) 
Folate (μg/L) 10.5 (10.9, 13.2) 16.8 (16.4, 17.7) 
Low folate status (%) 10 (11) 0 
Homocysteine (μmol/L) 6.23 (6.02, 7.54) 5.76 (5.64, 6.85) 
a Mean ± SD (all such values); b Geometric mean (95% CI) (all such values); c Numbers (percentages) (all  
such values). 
Table 2. Clinical characteristics of mothers and neonate according to maternal B12 levels. 
 
Mothers Neonate 
Maternal B12  
≥191 (ng/L) 
Maternal B12  
<191 (ng/L) 
Maternal B12  
≥191 (ng/L) 
Maternal B12  
 <191 (ng/L) 
n = 55 n = 36 n = 55 n = 36 
Age (years) 33.0 ± 6.2 a 32.3 ± 5.6 - - 
Weight (Kg) 74.3 ± 15.8 82.9 ± 20.8 * 3.58 ± 0.31 3.57 ± 0.18 
Height (m) 1.62 ± 0.07 1.61 ± 0.11 - - 
BMI (early pregnancy) (kg/m2) 28.4 ± 6.1 30.8 ± 6.4 * - - 
Glucose (mmol/L) 4.40 ± 0.46 4.36 ± 0.34 3.85 ± 0.52 3.94 ± 0.52 
Insulin (mIU/L) 10.4 (11.7, 18.0) b 13.7 (12.7, 18.6) 8.27 (8.33, 12.75) 7.64 (7.30, 12.40) 
Triglycerides (mmol/L) 2.49 (2.37, 2.93) 3.04 (2.82, 3.48) * 0.21 (0.20, 0.24) 0.26 (0.23, 0.32) ** 
Cholesterol (mmol/L) 6.23 (5.99, 6.72) 6.86 (6.51, 7.43) * 1.72 (1.64, 1.92) 1.62 (1.51, 1.83) 
LDL cholesterol (mmol/L) 3.29 (3.16, 3.82) 3.91 (3.67, 4.38) * 0.79 (0.76, 0.90) 0.87 (0.77, 1.09) 
HDL cholesterol (mmol/L) 1.61 (1.54, 1.80) 1.49 (1.42, 1.70) 0.79 (0.76, 0.91) 0.67 (0.62, 0.77) * 
HOMA-IR 1.18 (1.37, 2.14) 1.68 (1.57, 2.27) 0.94 (0.95, 1.41) 1.08 (0.98, 1.63) 
Vitamin B12 (ng/L) 288 (265, 378) 146 (139, 155) *** 367 (354, 544) 202 (187, 234) *** 
Low B12 status (%) 0 36 (40) c 8 (14.5)  18 (50) 
Folate (μg/L) 11.7 (11.5, 14.6) 9.0 (8.5, 12.4) * 17.6 (17.0, 18.5) 15.7 (14.9, 17.2) ** 
Low folate status (%) 3 (5.5) 7 (19.4) 0 0 
Homocysteine (μmol/L) 5.50 (5.26, 6.18) 7.53 (6.69, 10.1) *** 4.97 (4.74, 5.59) 7.09 (6.58, 8.96) *** 
a Mean ± SD (all such values); b Geometric mean (95% CI) (all such values); c Numbers (percentages) (all such values);  
* p-value compared to maternal B12 (≥191 ng/L) group; * p < 0.05; ** p < 0.01; *** p < 0.001. 
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Table 3. Vitamin B12, folate and homocysteine in mothers and neonate according to 
maternal smoking status, parity and folate supplement use. 
 Smoking n = 91 
Vitamin B12  
(ng/L) 
Folate  
(μg/L) 
Homocysteine 
(μmol/L) 
Maternal 
No (%) 55 245 (227, 357) 10.7 (10.6, 13.9) 6.15 (5.61, 8.08) 
Yes (%) 45 189 (176, 224) ** 10.1 (9.7, 13.3) 6.33 (5.90, 7.45) 
Neonate 
No (%) 55 327 (305, 502) 16.9 (16.4, 18.2) 5.42 (5.06, 6.58) 
Yes (%) 45 252 (232, 364) * 16.5 (15.8, 17.7) 6.21 (5.80, 7.68) 
 Parity     
Maternal 
Para 0 (%) 18 248 (203, 332) 13.7 (11.8, 17.9) 6.25 (5.21, 8.03) 
Para 1 (%) 48 224 (201, 347) 11.1 (10.8, 14.1) 6.12 (5.73, 7.43) 
Para ≥2 (%) 34 195 (179, 239) * 8.2 (7.6, 11.6) ** 6.4 (5.31, 8.97) 
Neonate 
Para 0 (%) 18 327 (264, 479) 17.9 (16.6, 19.6) 5.61 (4.50, 7.59) 
Para 1 (%) 48 284 (258, 487) 16.9 (16.3, 18.1) 5.91 (5.53, 7.30) 
Para ≥2 (%) 34 283 (250, 396) 16.0 (15.2, 17.4) * 5.67 (5.08, 7.15) 
 Folate supplement users  
Maternal 
Yes (%) 85 224 (216, 305) 11.1 (11.3, 14.0) 6.06 (5.77, 7.44) 
No (%) 15 187 (154, 245) 6.8 (5.5, 9.3) *** 7.42 (6.02, 9.61) * 
Neonate 
Yes (%) 85 311 (306, 445) 17.4 (17.0, 18.2) 5.57 (5.40, 6.53) 
No (%) 15 213 (134, 391) 13.5 (12.0, 15.6) *** 7.01 (5.34, 10.33) * 
Data are geometric mean (95% CI); * p-value compared to geometric mean in the respective group(s);  
* p < 0.05; ** p < 0.01; *** p < 0.001. 
3.2. Maternal B12 and Metabolic Risk of Offspring 
Maternal B12 adjusted for age and BMI was inversely associated with metabolic risk factors such as 
triglycerides (r = −0.219; p = 0.047), HOMA-IR (r = −0.232; p = 0.041), homocysteine (r = −0.423;  
p = 0.0001) and positively with HDL-cholesterol (r = 0.315; p = 0.004) (Figure 1a–d) in the offspring. 
Despite similar birth weight, offspring of low B12 mothers had significantly lower HDL-cholesterol, 
higher triglycerides and homocysteine than those of normal B12 mothers (Table 2). Multiple regression 
analysis was carried out to assess whether maternal B12 independently associated with these metabolic 
risk factors in the offspring by adjusting for likely confounders. The model included maternal age, parity, 
smoking, folic acid supplement use, BMI, glucose, insulin, folate and homocysteine as independent 
variables. In addition, for offspring’s lipid parameters, respective maternal variable was also included in 
the model (maternal triglycerides for offspring’s triglycerides, etc.). After all these adjustments, maternal 
B12 was independently associated with the offspring’s HDL and homocysteine. Though similar trends 
were seen for the triglycerides and HOMA-IR, these were not statistically significant. No sex-specific 
changes were seen in any of these analyses (data not shown). Maternal B12 explained 5.1% of the 
variation in offspring’s HDL and 10.6% in homocysteine (Table 4).  
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Table 4. Association of maternal B12, folate and homocysteine with neonate metabolic risk factors. 
Maternal 
Variable 
(SDS) 
Neonate’s Metabolic Risk Factors (SDS)  
Triglycerides * Cholesterol * HDL * LDL * Insulin * Glucose * Homocysteine * 
Maternal 
B12 * 
β 
95% 
CI 
p β 95% CI p β 95% CI p β 95% CI p β 95% CI p β 95% CI p β 
95% 
CI 
p 
Model 1 −0.148 
(−0.38, 
0.09) 
0.2
10 
0.10
9 
(−0.11, 
0.33) 
0.3
17 
0.29
6 
(0.07, 
0.52) 
0.0
10 
−0.0
44 
(−0.26, 
0.17) 
0.6
91 
0.07
0 
(−0.21, 
0.21) 
0.5
16 
−0.0
05 
(−0.22, 
−0.21) 
0.960 
−0.3
81 
(−0.58, 
−0.18) 
<0.001 
Model 2 −0.086 
(−0.38, 
0.21) 
0.5
62 
0.17
8 
(−0.08, 
0.44) 
0.1
73 
0.29
4 
(0.05, 
0.54) 
0.0
18 
0.07
0 
(−0.26, 
0.39) 
0.6
72 
−0.0
63 
(−0.17, 
0.29) 
0.5
93 
−0.0
88 
(−0.14, 
−0.31) 
0.438 
−0.2
00 
(−0.35, 
−0.05) 
0.009 
Model 3 −0.079 
(−0.39, 
0.23) 
0.6
09 
0.17
0 
(−0.09, 
0.43) 
0.1
98 
0.29
5 
(0.08, 
0.51) 
0.0
09 
0.05
6 
(−0.28, 
0.39) 
0.7
36 
−0.0
62 
(−0.17, 
0.29) 
0.6
02 
−0.0
93 
(−0.12, 
0.30) 
0.378    
Maternal Folate * 
Model 1 −0.109 
(−0.33, 
0.11) 
0.3
26 
−0.2
10 
(−0.42, 
0.001) 
0.0
51 
−0.0
25 
(−0.25, 
0.19) 
0.8
25 
−0.1
73 
(−0.38, 
0.04) 
0.1
11 
0.04
0 
(−0.17, 
0.25) 
0.7
05 
−0.1
24 
(−0.33, 
0.09) 
0.243 
−0.3
27 
(−0.53, 
−0.13) 
0.002 
Model 2 −0.084 
(−0.43, 
0.26) 
0.6
25 
−0.2
04 
(−0.49, 
0.08) 
0.1
60 
−0.2
36 
(−0.51, 
0.04) 
0.0
91 
−0.0
79 
(−0.40, 
0.24) 
0.6
25 
0.13
3 
(−0.15, 
0.42) 
0.3
57 
−0.0
35 
(−0.31, 
0.24) 
0.799 
−0.0
04 
(−0.19, 
0.18) 
0.966 
Model 3 −0.093 
(−0.45, 
0.26) 
0.6
00 
−0.2
00 
(−0.49, 
0.09) 
0.1
69 
−0.2
09 
(−0.46, 
0.04) 
0.0
99 
−0.0
82 
(−0.41, 
0.24) 
0.6
16 
0.13
6 
(−0.15, 
0.43) 
0.3
53 
−0.0
39 
(−0.29, 
0.22) 
0.763    
Maternal Homocysteine * 
Model 1 0.218 
(−0.00, 
0.44) 
0.0
50 
0.29
0 
(−0.07, 
0.51) 
0.0
09 
0.11
9 
(−0.13, 
0.36) 
0.3
36 
0.26
5 
(0.06, 
0.47) 
0.0
13 
0.00
1 
(−0.21, 
0.21) 
0.9
93 
0.12
1 
(−0.09, 
0.34) 
0.269 
0.75
2 
(0.62, 
0.89) 
<0.001 
Model 2 0.137 
(−0.19, 
0.47) 
0.4
73 
0.20
6 
(−0.08, 
0.49) 
0.1
56 
0.09
3 
(−0.23, 
0.41) 
0.5
56 
0.22
4 
(−0.09, 
0.54) 
0.1
60 
0.03
7 
(−0.23, 
0.31) 
0.7
85 
0.05
7 
(−0.21, 
0.32) 
0.669 
0.69
6 
(0.52, 
0.87) 
<0.001 
Model 3 0.126 
(−0.23, 
0.48) 
0.4
74 
0.23
0 
(−0.07, 
0.53) 
0.1
29 
0.15
8 
(−0.13, 
0.45) 
0.2
78 
0.24
8 
(−0.08, 
0.57) 
0.1
30 
0.04
3 
(−0.24, 
0.32) 
0.7
59 
0.08
9 
(−0.16, 
0.34) 
0.469    
* Log transformed for statistical comparisons. β represents SDS change in the dependent variable per SDS change in the independent variable. Model 1: unadjusted; Model 2: Maternal age, 
BMI, glucose, insulin, parity, folic acid supplement use, smoking, vitamin B12, folate and homocysteine; Model 3: Model 2 + respective maternal variable such as a—Model 2 + maternal 
triglycerides, b—Model 2 + maternal cholesterol, c—Model 2 + maternal HDL, d—Model 2 + maternal LDL, e—Model 2 + maternal insulin, f—Model 2 + maternal glucose, g—Model 2 + 
maternal homocysteine. 
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Figure 1. Correlation between maternal B12 (adjusted for age and BMI) and metabolic risk 
factors of neonates. (a) Maternal B12 and neonatal triglycerides, (b) Maternal B12 and 
neonatal Homeostasis Model Assessment 2-Insulin Resistance (HOMA-IR), (c) Maternal 
B12 and neonatal homocysteine, (d) Maternal B12 and neonatal HDL. * Log-transformed 
for statistical comparisons.  
3.3. Maternal Folate and Homocysteine and Metabolic Risk of Offspring 
Maternal folate negatively associated with offspring’s cholesterol (r = −0.214; p = 0.045), LDL  
(r = −0.233; p = 0.030) and homocysteine (r = −0.346; p = 0.001). Maternal homocysteine positively 
associated with offspring’s triglycerides (r = 0.239; p = 0.030), cholesterol (r = 0.247; p = 0.022) and 
LDL (r = 0.244; p = 0.026), however, these associations diminished after adjusting for all likely 
confounders (Table 4). 
4. Discussion 
Our study is the first to show that maternal vitamin B12 levels adversely associated with markers of 
metabolic risk at birth, in particular lipid profiles. Our observed rates of low B12 status in mothers (40%) 
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is common at the time of delivery though it is not as high as in the South Asian population [10,11,26]. 
Haemodilution and increased nutrient demand by the growing fetus [27] are known contributors to low 
B12 levels during pregnancy. In addition, consumption of processed foods, improving hygiene and 
reheating of cooked food, all known to reduce the bioavailable B12 in food products, could have 
contributed to lower B12 levels in this population [20,28]. The presence of higher homocysteine in the 
low B12 group suggest that these low levels are clinically significant and represent true insufficiency at 
the tissue level.  
Our findings show that low maternal B12 status was associated with offspring’s insulin resistance, 
lower HDL and higher triglycerides (Figure 1a,b,d). However, when multivariate analysis was used to 
assess the effect of B12 across the spectrum, only HDL was statistically significant after adjusting for 
the possible confounders (Table 4). In support of this, adverse lipid profile (higher total cholesterol and 
triglycerides) was noticed in rats born to vitamin B12 restricted dams [18,19]. In addition, we have 
recently demonstrated that adipocytes cultured in low B12 condition showed increased cholesterol levels 
and was due to hypomethylation of cholesterol transcription factor (SREBF1 and LDLR) [29]. The 
clinical findings observed in this study thus add evidence that low maternal B12 status adversely affects 
lipid profile in the offspring. We did not see any significant association between maternal and neonatal 
lipids (data not shown). While this was surprising, it was similar to other observations, where only lipids 
from GDM mothers associated with foetal lipids and not from non-GDM mothers [30,31].  
Our study also showed that maternal B12 showed a stronger inverse association with neonatal 
homocysteine than folate (Supplementary Figure S2a,b). In multiple regression analysis, after adjusting 
for the possible confounders, only maternal B12 and not folate, was independently associated with 
neonatal homocysteine (Table 4). The association between maternal folate and neonatal homocysteine 
became insignificant, when maternal homocysteine was added in the stepwise regression model  
(Table 4). This suggests that the effect of folate on neonatal homocysteine is likely to be mediated 
through maternal homocysteine while the effect of B12 could be partly independent of maternal 
homocysteine. Similar to our findings, Molloy et al. showed in an Irish population that low maternal 
B12 levels predicted hyperhomocysteinemia in both the newborns and the mothers [32]. Thus, our 
findings confirm that in folate replete populations, B12 is the strongest driver of homocysteine [10], an 
established metabolic risk factor [33]. Our study also showed that the BMI was higher in the low B12 
group (Table 2). Similar observations were seen other studies [29–31]. The cause and effect of this 
relationship is not known. Theoretically this could have contributed to higher maternal lipids and in turn 
higher lipids in cord blood. However, we did not see any correlation between maternal and cord lipids 
and our regression analysis adjusted for maternal lipids (Table 4). 
The plausible biochemical reasons that low maternal B12 status increase the metabolic risk in the 
offspring might be, firstly, in the cytoplasm, vitamin B12 acts as a cofactor for conversion of 
homocysteine to methionine, the direct precursor of S-adenosylmethionine (SAM) which is the common 
donor required for methylation of DNA, protein and lipids [10,26,34]. Secondly, in mitochondria, 
vitamin B12 also acts a cofactor for the conversion of methylmalonyl Co-A (MM-CoA) to succinyl  
Co-A. Thus, low vitamin B12 causes higher MM-CoA levels. This in turn can inhibit carnitine palmitoyl 
transferase-1 (CPT-1), the rate-limiting enzyme for fatty acid β-oxidation, thereby increasing  
lipogenesis [10,35]. As these mechanisms involve methylation of DNA, this might lead to higher 
metabolic risk in the offspring by adverse epigenetic programming in addition to directly affecting β-
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oxidation of fatty acids. In vivo and interventional studies are required to identify the exact mechanisms 
and prove the causality. 
Similar to B12, low maternal folate levels also showed adverse correlations with the metabolic risk 
markers of the offspring but these differences disappeared in regression models. Women with highest 
B12 and folate levels gave birth to children with lowest homocysteine levels compared to those with 
lowest B12 and folate levels (7.80 vs. 4.85 μmol/L, p < 0.001; Supplementary Table S1). Taken together, 
these findings suggest that optimising the circulating levels of these two B vitamins during pregnancy, 
is likely to be beneficial to the offspring.  
Strengths and limitations: Our study is cross sectional and from a single-centre. However, this is the 
first study to report the associations between maternal B12 and lipid profiles in the offspring. A 
prospective cohort of women from before or early pregnancy would have been a better model. As the 
pathophysiological link, if any, between maternal nutrient status and offspring metabolic risk seem to 
happen earlier in pregnancy, such longitudinal study would have strengthened our findings [9,10]. Our 
findings call for such studies to be conducted urgently. Studies have reported that B12 levels 
progressively decline during pregnancy [36]. Therefore, the effect size we observed during late 
pregnancy might have been an overestimate if early pregnancy samples were tested. We did not use the 
microbiological assay for B12 measurements, which is known to be more sensitive at the lower levels 
of B12. This may have underestimated the rate of low B12 status [37] and in turn, the association with 
the metabolic risk factors in the offspring. We did not have a detailed socioeconomic status of the 
participants. It is known that lower socioeconomic status is an important confounder of adverse lipid 
profiles and BMI but the link between socioeconomic status and B12 is not known. Therefore, this is 
also a limitation of our observation and future studies should collect detailed socioeconomic status. 
Finally, although our sample size was adequate to demonstrate the low B12 status, it was probably too 
small to demonstrate the independent associations between maternal folate and homocysteine status and 
cord blood lipids. 
In summary, our study shows that maternal vitamin B12 plays an important role in lipid metabolism 
in the offspring and that their restriction in utero may predispose them to the increased metabolic risk. 
However, these findings need to be replicated, ideally in a larger cohort of pregnant women from early 
pregnancy. In addition, in vivo and interventional studies are required to prove the exact mechanisms and 
the potential causal link. If proven, optimizing B12 levels of young women around the peri-conceptional 
period, could offer novel opportunities to reduce the burden of obesity and related metabolic disorders 
of the next generation. 
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